Med BioGene Inc. has announced that it has entered into a research collaboration and option agreement with Duke University to further develop and validate MBI's genetic biomarkers for lymphoma and leukemia using its Gene Expression Profiling System™.
"We are very pleased and enthusiastic about collaborating with Duke University, one of the world's most prestigious academic institutions," said Erinn Broshko, Chief Executive Officer of MBI.
"This collaboration further demonstrates Med BioGene's focus and commitment to rapidly develop a novel tool using microarray analysis for disease diagnosis and prognosis and therapeutic development. We expect our Gene Expression Profiling System™ to be more accurate, faster and more cost effective than current methods of diagnosing lymphoma and leukemia. Furthermore, the development of these biomarkers is the first step towards personalized medicine and is intended to replace the conventional "one drug fits all" approach to disease management," concluded Mr. Broshko.
"In diagnosing and treating lymphoma and leukemia, there is a need for technologies that can provide maximum insight into gene regulation and gene alterations on the transcriptional level. Microarray analysis used to perform gene expression profiling may be the method of choice in this regard because it allows simultaneous detection of the expression of nearly all human genes in one experimental approach," noted Dr. David Rizzieri, MD, Associate Professor of Medicine at the Duke University Medical Center.
"Med BioGene's technology may have applications in clinical research, disease diagnosis, treatment and drug development. Our investigators are eager to begin the collaboration," added Dr. Rizzieri.